NCT04091750 - Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

August 8, 2023

Study Completion Date

December 31, 2025

Conditions

Melanoma

Interventions

DRUG

Nivolumab

"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"

DRUG

Ipilimumab

Induction: 1mg/kg IV every 3 weeks x 4 cycles

DRUG

Cabozantinib

Induction and Maintenance: 40mg PO daily

Trial Locations (3)

Lombardi Comprehensive Cancer Center, Washington D.C.

Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute, Baltimore

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack